Payment overview · 2025
General Payments
$41.63
2 reported records · 2 companies
Healthcare provider profile · identity verified
Ann E Blackman, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAINT ROBERT, MO · NPI 1588640510
Verified facts
What the public records show
CMS Open Payments records show Ann E Blackman, MD received $41.63 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 52.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.98 | 52.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.65 | 47.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $41.63 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
160 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 150 |
| Lisinopril | Lisinopril | 390 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 127 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 310 | 65 |
| Gabapentin | Gabapentin | 309 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 88 |
| Omeprazole | Omeprazole | 283 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 75 |
| Tramadol Hcl | Tramadol Hcl | 257 | 69 |
| Losartan Potassium | Losartan Potassium | 229 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 68 |
| Alprazolam | Alprazolam | 213 | 43 |
| Metformin Hcl | Metformin Hcl | 185 | 52 |
| Furosemide | Furosemide | 184 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 50 |
| Eliquis | Apixaban | 160 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 31 |
| Potassium Chloride | Potassium Chloride | 144 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 49 |
| Trazodone Hcl | Trazodone Hcl | 140 | 46 |
| Sertraline Hcl | Sertraline Hcl | 137 | 51 |
| Meloxicam | Meloxicam | 132 | 41 |
| Montelukast Sodium | Montelukast Sodium | 132 | 46 |
| Famotidine | Famotidine | 131 | 38 |
| Glimepiride | Glimepiride | 125 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 42 |
| Metformin Hcl Er | Metformin Hcl | 119 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 37 |
| Carvedilol | Carvedilol | 101 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 16 |
| Pregabalin | Pregabalin | 97 | 23 |
| Allopurinol | Allopurinol | 91 | 26 |
| Simvastatin | Simvastatin | 89 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 24 |
| Ozempic | Semaglutide | 80 | 21 |
| Ezetimibe | Ezetimibe | 77 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 20 |
| Clonazepam | Clonazepam | 73 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 25 |
| Lovastatin | Lovastatin | 69 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 23 |
| Buspirone Hcl | Buspirone Hcl | 62 | 21 |
| Lorazepam | Lorazepam | 62 | 15 |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 14 |
| Alendronate Sodium | Alendronate Sodium | 53 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 53 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 12 |
| Atenolol | Atenolol | 48 | 17 |
| Glipizide | Glipizide | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Spironolactone | Spironolactone | 46 | 16 |
| Ondansetron Odt | Ondansetron | 43 | 13 |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Finasteride | Finasteride | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 15 |
| Baclofen | Baclofen | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 15 |
| Nitroglycerin | Nitroglycerin | 30 | 13 |
| Nystatin | Nystatin | 30 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Cefdinir | Cefdinir | 16 | 14 |
| Fluconazole | Fluconazole | 16 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Metronidazole | Metronidazole | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $41.63 · 2 records | PFIZER INC. | ABRYSVO, COMIRNATY, PREVNAR 20 | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error